Aimovig, a medication for migraine prevention, generated $312 million in net sales in 2023. This figure represents a 4% decrease compared to the previous year's sales of $324 million [1].
What is Aimovig approved for?
Aimovig is approved for the preventive treatment of migraine in adults [1].
Who makes Aimovig?
Aimovig is developed and marketed by Amgen [1].
How does Aimovig work?
Aimovig targets the calcitonin gene-related peptide (CGRP) receptor. By blocking the action of CGRP, a molecule involved in migraine pathways, Aimovig aims to reduce the frequency of migraine attacks [1].
When does Aimovig's patent expire?
Information regarding the specific patent expiry dates for Aimovig is not available in the provided text. However, patent information for drugs can be complex and may involve multiple patents covering different aspects of the drug and its use. Resources like DrugPatentWatch.com track patent statuses and expiry dates for pharmaceutical products [2].
What are Aimovig's competitors?
The migraine prevention market includes several other CGRP-targeting therapies, such as Ajovy (fremanezumab) and Emgality (galcaneumab). These medications offer alternative treatment options for patients [1].
What is the difference between Aimovig and other migraine treatments?
Aimovig, along with other CGRP inhibitors, represents a newer class of migraine prevention drugs. Unlike older medications, which were often repurposed drugs for conditions like epilepsy or depression, CGRP inhibitors are specifically designed for migraine [1].
What are the sales trends for Aimovig?
Aimovig's net sales declined by 4% in 2023, reaching $312 million. This follows a period where sales were $324 million in 2022 [1].
What is the mechanism of action for CGRP inhibitors?
CGRP inhibitors, including Aimovig, work by blocking the CGRP pathway, which is implicated in migraine pathophysiology. This blockade is believed to prevent or reduce migraine attacks [1].
What are the side effects of Aimovig?
The provided information does not detail the specific side effects associated with Aimovig. Patients considering or using Aimovig should consult with their healthcare provider for a comprehensive understanding of potential risks and side effects [1].
What clinical data supports Aimovig's use?
Clinical trials have demonstrated Aimovig's efficacy in reducing monthly migraine days and monthly attack days in adults with episodic and chronic migraine [1].
Sources:
[1] https://www.amgen.com/newsroom/press-releases/2024/02/amgen-announces-fourth-quarter-and-full-year-2023-financial-results
[2] https://drugpatentwatch.com/